New algorithm identifies cells responsible for aggressive tumor growth

Cancer Research UK-funded scientists have unveiled the first computational algorithm capable of identifying which cell populations within a tumor drive aggressive growth.

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 6, 2024

U.S. flu vaccines expected to shift from quadrivalent to trivalent, researcher says

U.S. flu vaccines are likely to move from quadrivalent to trivalent due to a change in circulating influenza viruses, says a University of Michigan researcher.

February 29, 2024

Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

November 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.